PBAC's latest decision on Alectinib, crizotinib, ceritinib: Recommended with restriction (2019). Considered for Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC) positive for ALK gene rearrangement (alectinib, crizotinib, ceritinib) or ROS1-positive (crizotinib).
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2019
Submissions
1
2019 → 2019
Eligible population
Patients with Stage IIIB (locally advanced) or Stage IV (metastatic) NSCLC with ALK gene rearrangement (alectinib, crizotinib, ceritinib) or ROS1-positive disease (crizotinib).
Therapy area
Oncology
Line of therapy
Any
Evidence base
Other
Economic model
Not modelled
ICER note
Not a clinical or economic evaluation submission. This is a procedural request to amend the number of repeats for already-listed medicines; no ICER calculated or applicable.